{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:20:37Z","timestamp":1777663237690,"version":"3.51.4"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.<\/jats:p>","DOI":"10.1055\/s-0044-1787189","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:52:00Z","timestamp":1718232720000},"page":"1163-1172","source":"Crossref","is-referenced-by-count":4,"title":["Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel\/Emerging Hemostatic Agents"],"prefix":"10.1055","volume":"50","author":[{"given":"Geoffrey","family":"Kershaw","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, Australia"},{"name":"ANZAC Research Institute, University of Sydney, Hospital Road, Concord, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays","volume":"18","author":"F Peyvandi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"P M Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"key":"ref3","first-page":"569","volume-title":"A review of factor VIII and factor IX assay methods for monitoring extended half-life products in hemophilia A and B","author":"S Abraham","year":"2023"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0037-1598058","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"S Kitchen","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref5","first-page":"312","article-title":"Susoctocog-alfa (Obizur\u00ae) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience","volume":"18","author":"E Zanon","year":"2020","journal-title":"Blood Transfus"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys","volume":"20","author":"B Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"T Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"20","key":"ref8","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"A Muto","year":"2014","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"A Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"J Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"M Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"J M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"A Bowyer","year":"2020","journal-title":"Haemophilia"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' organisation guideline","volume":"26","author":"P V Jenkins","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"C Schmitt","year":"2021","journal-title":"Haemophilia"},{"key":"ref19","first-page":"589","volume-title":"Measuring emicizumab levels in the hemostasis laboratory","author":"G Kershaw","year":"2023"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.pathol.2022.02.006","article-title":"Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement","volume":"54","author":"G Kershaw","year":"2022","journal-title":"Pathology"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ijlh.14021","article-title":"The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement?","volume":"45","author":"A E Bowyer","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"M Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.jtha.2023.09.011","article-title":"Functional determination of emicizumab in presence of factor VIII activity","volume":"21","author":"N S Hamedani","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.rpth.2023.102181","article-title":"Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults","volume":"7","author":"P Persson","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"S 01","key":"ref25","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1182\/blood-2022-163554","article-title":"Mim8 clinical development program: an overview of the frontier studies","volume":"140","author":"S V Seremetis","year":"2022","journal-title":"Blood"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, PK, and PD of Mim8, a factor VIIIa mimetic","volume":"22","author":"S R Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2022.12.023","article-title":"The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation","volume":"21","author":"A E Bowyer","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/hae.14884","article-title":"A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays","volume":"29","author":"A E Bowyer","year":"2023","journal-title":"Haemophilia"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/hae.12784","article-title":"Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile","volume":"22","author":"D Lillicrap","year":"2016","journal-title":"Haemophilia"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"R Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"R Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2040620717720861","article-title":"Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A","volume":"8","author":"E Fosbury","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"P L Turecek","year":"2016","journal-title":"Haemophilia"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/hae.13426","article-title":"Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A","volume":"24","author":"V R Vanguru","year":"2018","journal-title":"Haemophilia"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14831","article-title":"A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories","volume":"30","author":"S Pipe","year":"2024","journal-title":"Haemophilia"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"B A Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"ref37","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"E Seth Chhabra","year":"2020","journal-title":"Blood"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"A von Drygalski","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:15:16Z","timestamp":1730801716000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":38,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,10,11]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787189","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}